



PATENT 1422-0625P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: OZEKI, Makoto et al. Conf.: 2621

Appl. No.: 10/790,730 Group: Unassigned

Filed: March 3, 2004 Examiner: Unassigned

For: PHARMACEUTICAL COMPOSITION FOR TREATING

MOOD DISORDERS

LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

June 3, 2004

Sir:

Under the provisions of MPEP § 2001.06(b), the Examiner is hereby advised of the following co-pending U.S. Application(s):

Appl. No.	Filing Date	Group
09/655,336	September 5, 2000	1617
09/980,620	December 5, 2001	1615

The subject matter contained in the above-listed co-pending U.S. application(s) may be deemed to relate to the present application, and thus may be material to the prosecution of this instant application.

Copies of cited U.S. patent applications (specification, claims, and the drawings) will be provided if requested by the Examiner.

The above-listed co-pending applications are not to be construed as prior art. By bringing the above-listed applications to the attention of the Examiner, Applicants do NOT waive any confidentiality concerning the above-listed co-pending applications or this application. See MPEP § 101. Furthermore, if said applications should not mature into patents, such applications should be preserved in secrecy under the provisions of 35 U.S.C. § 122 and 37 C.F.R. § 1.14.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

GMM/CAM:bmp 1422-0625P Attachment(s)

(Rev. 02/12/2004)